A randomized, placebo-controlled trial of 958 older adults found that taking a daily multivitamin for two years slowed biological aging by roughly four months compared to placebo, based on molecular markers in blood samples. The finding, published in Nature Medicine on March 9, 2026, comes from a sub-study of the large COSMOS clinical trial and represents one of the first rigorous tests of whether an inexpensive supplement can shift the epigenetic markers scientists use to estimate how fast cells deteriorate. The effect is real but small, and independent experts are split on whether it translates into any meaningful gain in health or lifespan.
What the COSMOS Sub-Study Measured
The trial drew its participants from COSMOS, a factorial-design study that ran from June 2015 to December 2020 and tested both cocoa extract and a standard multivitamin-multimineral supplement. In the aging sub-study, researchers collected blood samples at three points: baseline, year one, and year two. They then analyzed longitudinal DNA methylation patterns across the genome to estimate each participant’s biological age using five separate epigenetic clocks, as described in the primary report. These clocks work by reading chemical tags on DNA that accumulate or shift as cells age, and different clocks weight different genomic regions, which means they can produce varying estimates of the same person’s biological age.
The 958 participants had a mean age of approximately 70 years. Those randomized to the multivitamin arm showed a modest but consistent slowing across the clock panel relative to those on placebo. Cocoa extract, the other active arm in the factorial design, did not produce a similar effect on any of the clocks. That asymmetry is itself informative: it suggests the aging signal is tied to the broad nutritional coverage of a multivitamin rather than the flavanol-rich cocoa compound, though the study was not designed to pinpoint which specific vitamins or minerals drove the change.
The Nature Medicine paper relied on well-established epigenetic algorithms, but the authors also compared how different clocks behaved over time. According to a news analysis from Nature, some clocks appeared more sensitive to supplementation than others, underscoring that not all measures of biological age are interchangeable. A separate login-gated version of the article is accessible through the publisher’s authentication portal, but both routes describe the same underlying dataset and conclusions.
Four Months in Two Years
The headline number, roughly four months of slower biological aging over a two-year period, comes from a Harvard-affiliated summary that drew on the trial’s statistical modeling. Senior author Howard Sesso, an epidemiologist at Brigham and Women’s Hospital, described the results as initial evidence that daily multivitamin use may slow biological aging in older adults, and collaborator Yanbin Dong also contributed to the analysis.
That four-month figure deserves careful framing. In a population averaging 70 years old, shaving four months off two years of biological aging is a shift of roughly 17 percent in the rate of epigenetic change over the study window. That sounds large as a percentage, but in absolute terms it is a fraction of the aging that still occurred. And because the study lasted only two years, there is no evidence yet about whether the benefit compounds over a decade or plateaus quickly. Coverage in Nature’s news section emphasized that the magnitude of the effect was measured in months, not years, and that clock-to-clock differences added complexity to interpreting the result.
Statistically, the slowing of biological aging was consistent across several analytic approaches, but the confidence intervals were narrow enough to rule out a very large anti-aging effect. Instead, the data support a modest shift that could matter at the population level if it persists over longer periods, particularly in people with marginal nutrient intake. Whether such a shift would be detectable in hard outcomes like disability or mortality remains unknown.
Epigenetic Clocks Are Surrogates, Not Outcomes
The central tension in this research is whether moving an epigenetic clock needle actually means a person will live longer, stay healthier, or avoid disease. A journal-commissioned commentary published alongside the study raised exactly this concern: while the clocks shifted in response to supplementation, the open question of whether modified clocks translate into longer healthspan remains unanswered. Epigenetic clocks were originally developed as population-level predictors of mortality risk, not as validated treatment targets.
The distinction matters. Lowering a biomarker is not the same as preventing a heart attack or delaying dementia, and the history of medicine is full of surrogate endpoints that looked promising but failed to predict real clinical benefit. The commentary’s authors urged caution in treating epigenetic age as a modifiable endpoint on par with blood pressure or LDL cholesterol, noting that more work is needed to understand what kinds of interventions change these clocks and how those changes map onto disease trajectories.
Some of the same arguments appear in a paywalled version of the piece accessible via Nature’s login page, which reiterates that epigenetic measures should currently be viewed as research tools rather than clinical diagnostics. Until multiple large trials demonstrate that clock-slowing interventions reliably reduce disease, regulators are unlikely to accept these biomarkers as endpoints for drug approval or guideline changes.
Dr. Marco Di Antonio, an expert in biological aging at Imperial College London who was not involved in the work, offered a similar note of caution. His comments in a newspaper interview suggested the link between multivitamins and clock changes could partly reflect correction of nutritional deficits rather than a direct anti-aging mechanism. If participants entered the trial with undetected gaps in key nutrients, supplementation might restore normal methylation patterns rather than actively reversing aging.
How This Fits With Earlier COSMOS Findings
The epigenetic aging result does not exist in isolation. Earlier analyses from the same COSMOS framework found that multivitamin supplementation was associated with modest cognitive benefits over approximately two years, based on the COSMOS-Clinic trial and a within-COSMOS meta-analysis. Those studies reported small improvements on memory and global cognitive scores in older adults taking a daily multivitamin compared with placebo, again suggesting a subtle but favorable signal.
A separate arm of the parent trial examined cocoa extract and incident type 2 diabetes risk, reporting no major protective effect. Together, these studies form a body of evidence from a single well-designed trial that keeps pointing in the same direction for multivitamins: small, positive signals across different biological systems, from cognition to epigenetic aging. None of the effects are dramatic on their own, but their consistency across endpoints is noteworthy.
At the same time, no COSMOS paper has yet demonstrated that multivitamins reduce mortality or prevent a major chronic disease with an effect size large enough to change clinical guidelines. The current data instead strengthen the case for a larger, longer trial specifically designed to test whether these small biological shifts add up to measurable health gains over five or ten years. Commentators in Nature’s subscriber portal echoed that message, arguing that the multivitamin signal is intriguing but not yet practice-changing.
What This Means for Consumers
For individuals wondering whether to start or continue a daily multivitamin, the new findings offer cautious encouragement rather than a mandate. In generally healthy older adults, a standard supplement appears to nudge biological aging markers and cognitive performance in a favorable direction, but the magnitude of benefit is modest and long-term clinical outcomes remain unproven. Multivitamins are not a substitute for core health behaviors such as not smoking, exercising regularly, eating a balanced diet, and managing blood pressure and blood sugar.
Safety is another consideration. Standard-dose multivitamins used in COSMOS were well tolerated, but very high doses of certain nutrients can be harmful, particularly in people with kidney disease, bleeding risks, or specific medication regimens. Anyone contemplating supplementation above typical over-the-counter doses should speak with a clinician who can review their diet, lab results, and drug interactions. Even for standard products, older adults on multiple medications may benefit from professional advice to avoid conflicts with blood thinners, thyroid drugs, or other therapies.
Cost and expectations also matter. A multivitamin is relatively inexpensive, and for people whose diets fall short of recommended intakes, it may be a reasonable insurance policy against subtle deficiencies that could influence methylation patterns and brain function. But consumers should be wary of anti-aging marketing claims that oversell the COSMOS findings. The evidence so far supports, at best, a small slowing of biological aging markers over two years, not a dramatic extension of life or reversal of age-related decline.
Looking ahead, researchers plan to track COSMOS participants for longer periods and to integrate epigenetic data with clinical outcomes such as cardiovascular events, dementia diagnoses, and functional status. Those follow-up analyses will help clarify whether the observed four-month shift in epigenetic age is a harbinger of tangible health benefits or simply an interesting molecular footnote. Until then, multivitamins can reasonably be viewed as one optional component of a broader prevention strategy, not a stand-alone longevity intervention.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
